Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Tóm tắt
Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally. Oral fingolimod was approved in September 2010 by the US Food and Drug Administration to reduce relapses and disability progression in relapsing forms of MS. In the clinical trials that led to approval, fingolimod reduced not only acute relapses and magnetic resonance imaging lesion activity but also disability progression and brain volume loss, suggesting preservation of tissue. Fingolimod's mechanism of action in MS is not known with certainty. Its active form, fingolimod‐phosphate (fingolimod‐P), is a sphingosine 1‐phosphate receptor (S1PR) modulator that inhibits egress of lymphocytes from lymph nodes and their recirculation, potentially reducing trafficking of pathogenic cells into the central nervous system (CNS). Fingolimod also readily penetrates the CNS, and fingolimod‐P formed in situ may have direct effects on neural cells. Fingolimod potently inhibits the MS animal model, experimental autoimmune encephalomyelitis, but is ineffective in mice with selective deficiency of the S1P1 S1PR subtype on astrocytes despite normal expression in the immune compartment. These findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing a combination of beneficial anti‐inflammatory and possibly neuroprotective/reparative effects, may contribute to its efficacy in MS. In clinical trials, fingolimod was generally safe and well tolerated. Its interaction with S1PRs in a variety of tissues largely accounts for the reported adverse effects, which were seen more frequently with doses 2.5 to 10× the approved 0.5mg dose. Fingolimod's unique mechanism of action distinguishes it from all other currently approved MS therapies. Ann Neurol 2011;69:759–777
Từ khóa
Tài liệu tham khảo
Montalban X, 2009, Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension (P06.128) [abstract], Neurology, 72, A313
Francis G, 2010, Lymphocytes and fingolimod—temporal pattern and relationship with infections (P442), Mult Scler, 16, S146
van Doorn R, 2010, Sphingosine 1‐phosphate receptors 1 and 3 are upregulated in multiple sclerosis lesions (P662), Mult Scler, 16, S228
Deogracias R, 2008, Expression of brain‐derived neurotrophic factor is regulated by fingolimod (FTY720) in cultured neurons (P728), Mult Scler, 14, S243
Kataoka H, 2005, FTY720, sphingosine 1‐phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration, Cell Mol Immunol, 2, 439
Pryce G, 2008, Control of chronic relapsing progressive EAE with fingolimod (P01.092), Neurology, 70, A29
Schubart AS, 2008, FTY720 suppresses ongoing EAE and promotes a remyelinating environment preventing axonal degeneration within the CNS (P06.166), Neurology, 70, A339
Rossi S, 2010, Fingolimod treatment prevents the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis (P880), Mult Scler, 16, S309
Schubart A, 2007, CNS mediated effects of FTY720 (fingolimod) (P07.101), Neurology, 68, A315
Anthony DC, 2010, Fingolimod (FTY720) therapy reduces demyelination and microglial activation in a focal delayed‐type hypersensitivity model of multiple sclerosis during the remission phase (P814), Mult Scler, 16, S283
Collins W, 2010, Long‐term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 1 and 3 studies (P843), Mult Scler, 16, S295
NDA 02257—FDA approved labeling text for Gilenya (fingolimod) capsules. September 21 2010. Available at:http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf. Accessed March 23 2011.
Gergely P, 2009, Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans (P437), Mult Scler, 15, S125
DiMarco JP, 2010, First‐dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS) (P830), Mult Scler, 16, S290
Schmouder R, 2010, Effects of fingolimod on antibody response following steady‐state dosing in healthy volunteers: a 4‐week randomised, placebo‐controlled study (P412), Mult Scler, 16, S135
Novartis. FTY720 in patients with primary progressive multiple sclerosis (INFORMS). ClinicalTrials.gov Identifier: NCT00731692. Available at:http://clinicaltrials.gov/ct2/show/NCT00731692. Accessed March 23 2011.
Khatri B, 2010, 24‐month efficacy and safety from the TRANSFORMS extension study of oral fingolimod (FTY720) in patients with relapsing‐remitting multiple sclerosis(P03.125), Neurology, 74, A239
Calabresi PA, 2010, Oral fingolimod (FTY720) in relapsing‐remitting multiple sclerosis: baseline patient demographics and disease characteristics from a 2‐year phase III trial (FREEDOMS II) (P05.038), Neurology, 74, A416
Novartis. Efficacy and safety of fingolimod (FTY720) in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II). ClinicalTrials.gov Identifier: NCT00355134. Available at:http://clinicaltrials.gov/ct2/show/NCT00355134. Accessed March 23 2011.
Novartis and Mitsubishi Tanabe Pharma. Efficacy and safety of FTY720 in patients with relapsing multiple sclerosis (MS). ClinicalTrials.gov Identifier: NCT00537082. Available at:http://clinicaltrials.gov/ct2/show/NCT00537082. Accessed March 23 2011.